Clinical Trial

Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)

Study acronym: SNACS
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome. The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity. The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the standard double doses.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2021-10-28; most recent amendment 2026-01-05.
Status change: Active, Not Recruiting → Recruiting 2024-08-16
Status change: Recruiting → Active, Not Recruiting 2024-07-04
Status change: Not Yet Recruiting → Recruiting 2023-11-08
Trial Details
NCT Number NCT05114096
Lead Sponsor McMaster University
Collaborators: Hamilton Health Sciences Corporation, Sunnybrook Research Institute, Women's and Children's Hospital, Australia, Canadian Institutes of Health Research (CIHR), Medical Research Future Fund, University of Adelaide
Conditions Preterm Birth, Premature Birth, Complication of Prematurity, Obstetric Labor, Premature, Pregnancy Complications
Enrollment 3,254 participants
Start Date 2023-07-20
Primary Completion 2026-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-07